Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Leases: 2019-2025

Historic Operating Leases for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $45.2 million.

  • Iovance Biotherapeutics' Operating Leases was N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $44.4 million for FY2024, which is 33.87% down from last year.
  • Iovance Biotherapeutics' Operating Leases amounted to $45.2 million in Q3 2025, which was up 0.26% from $45.1 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Operating Leases' 5-year high stood at $72.3 million during Q1 2024, with a 5-year trough of $44.2 million in Q1 2025.
  • In the last 3 years, Iovance Biotherapeutics' Operating Leases had a median value of $67.1 million in 2023 and averaged $58.3 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Operating Leases climbed by 3.85% in 2024 and then slumped by 38.83% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Operating Leases stood at $67.1 million in 2023, then crashed by 33.87% to $44.4 million in 2024, then crashed by 38.83% to $45.2 million in 2025.
  • Its Operating Leases was $45.2 million in Q3 2025, compared to $45.1 million in Q2 2025 and $44.2 million in Q1 2025.